Juillet 2022: Selon les recherches les plus récentes menées par Emergen Research, le marché mondial de la thérapie par cellules CAR T a atteint une taille de 1.29 milliard de dollars en 2021 et devrait enregistrer un TCAC des revenus de 24.9 % au cours de la période de prévision. L’incidence croissante du cancer partout dans le monde ainsi que le taux de mortalité croissant causé par le cancer devraient être les principaux moteurs de la croissance des revenus sur le marché mondial de la thérapie cellulaire CAR-T au cours de la période de prévision. L’expansion des activités d’essais cliniques à un rythme effréné, la prolifération des fusions et acquisitions et l’attrait des introductions en bourse sont autant de facteurs qui contribuent à la croissance des revenus sur le marché mondial de la thérapie cellulaire CAR T.
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global Thérapie CAR T-Cell market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the Thérapie CAR T-Cell market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
D'autres conclusions importantes du rapport indiquent que
In 2021, the segment of diffuse large B-cell lymphome was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with thérapie par lymphocytes T avec récepteur d'antigène chimérique, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell lymphomes non hodgkiniens who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
Les principales entreprises qui opèrent actuellement sur le marché sont étudiées plus en détail dans ce rapport, tout comme leurs profils d'entreprise, leurs portefeuilles de produits, leurs stratégies d'expansion et leurs alliances stratégiques. Quelques exemples de ces types d'alliances comprennent les fusions et acquisitions, les collaborations et les coentreprises. En plus de cela, il fournit des faits saillants sur les réalisations et la situation financière de l'entreprise, ainsi que des informations sur la portée du marché et la position mondiale de l'entreprise.
Entreprises présentées sur le marché mondial de la thérapie CAR T-Cell:
Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, Astellas Pharma Inc., BioNTech SE, Biocad, F. Hoffmann-La Roche Ltd. et Eli Lilly and Company .
Pour en savoir plus sur le rapport sur le marché mondial de la thérapie CAR T-Cell, rendez-vous sur : https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
